Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes
Copyright © 2022 International Society of Nephrology. All rights reserved..
This study applies a large proteomics panel to search for new circulating biomarkers associated with progression to kidney failure in individuals with diabetic kidney disease. Four independent cohorts encompassing 754 individuals with type 1 and type 2 diabetes and early and late diabetic kidney disease were followed to ascertain progression to kidney failure. During ten years of follow-up, 227 of 754 individuals progressed to kidney failure. Using the SOMAscan proteomics platform, we measured baseline concentration of 1129 circulating proteins. In our previous publications, we analyzed 334 of these proteins that were members of specific candidate pathways involved in diabetic kidney disease and found 35 proteins strongly associated with risk of progression to kidney failure. Here, we examined the remaining 795 proteins using an untargeted approach. Of these remaining proteins, 11 were significantly associated with progression to kidney failure. Biological processes previously reported for these proteins were related to neuron development (DLL1, MATN2, NRX1B, KLK8, RTN4R and ROR1) and were implicated in the development of kidney fibrosis (LAYN, DLL1, MAPK11, MATN2, endostatin, and ROR1) in cellular and animal studies. Specific mechanisms that underlie involvement of these proteins in progression of diabetic kidney disease must be further investigated to assess their value as targets for kidney-protective therapies. Using multivariable LASSO regression analysis, five proteins (LAYN, ESAM, DLL1, MAPK11 and endostatin) were found independently associated with risk of progression to kidney failure. Thus, our study identified proteins that may be considered as new candidate prognostic biomarkers to predict risk of progression to kidney failure in diabetic kidney disease. Furthermore, three of these proteins (DLL1, ESAM, and MAPK11) were selected as candidate biomarkers when all SOMAscan results were evaluated.
| Errataetall: |
CommentIn: Kidney Int. 2022 Aug;102(2):236-238. - PMID 35870813 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Kidney international - 102(2022), 2 vom: 01. Aug., Seite 370-381 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kobayashi, Hiroki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.07.2022 Date Revised 02.08.2023 published: Print-Electronic CommentIn: Kidney Int. 2022 Aug;102(2):236-238. - PMID 35870813 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.kint.2022.04.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341404292 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341404292 | ||
| 003 | DE-627 | ||
| 005 | 20231226011710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.kint.2022.04.022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341404292 | ||
| 035 | |a (NLM)35618095 | ||
| 035 | |a (PII)S0085-2538(22)00372-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kobayashi, Hiroki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2022 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Kidney Int. 2022 Aug;102(2):236-238. - PMID 35870813 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 International Society of Nephrology. All rights reserved. | ||
| 520 | |a This study applies a large proteomics panel to search for new circulating biomarkers associated with progression to kidney failure in individuals with diabetic kidney disease. Four independent cohorts encompassing 754 individuals with type 1 and type 2 diabetes and early and late diabetic kidney disease were followed to ascertain progression to kidney failure. During ten years of follow-up, 227 of 754 individuals progressed to kidney failure. Using the SOMAscan proteomics platform, we measured baseline concentration of 1129 circulating proteins. In our previous publications, we analyzed 334 of these proteins that were members of specific candidate pathways involved in diabetic kidney disease and found 35 proteins strongly associated with risk of progression to kidney failure. Here, we examined the remaining 795 proteins using an untargeted approach. Of these remaining proteins, 11 were significantly associated with progression to kidney failure. Biological processes previously reported for these proteins were related to neuron development (DLL1, MATN2, NRX1B, KLK8, RTN4R and ROR1) and were implicated in the development of kidney fibrosis (LAYN, DLL1, MAPK11, MATN2, endostatin, and ROR1) in cellular and animal studies. Specific mechanisms that underlie involvement of these proteins in progression of diabetic kidney disease must be further investigated to assess their value as targets for kidney-protective therapies. Using multivariable LASSO regression analysis, five proteins (LAYN, ESAM, DLL1, MAPK11 and endostatin) were found independently associated with risk of progression to kidney failure. Thus, our study identified proteins that may be considered as new candidate prognostic biomarkers to predict risk of progression to kidney failure in diabetic kidney disease. Furthermore, three of these proteins (DLL1, ESAM, and MAPK11) were selected as candidate biomarkers when all SOMAscan results were evaluated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a circulating biomarker | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a diabetic kidney disease | |
| 650 | 4 | |a end-stage kidney disease | |
| 650 | 4 | |a proteomics analysis | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Endostatins |2 NLM | |
| 650 | 7 | |a LAYN protein, human |2 NLM | |
| 650 | 7 | |a Lectins, C-Type |2 NLM | |
| 700 | 1 | |a Looker, Helen C |e verfasserin |4 aut | |
| 700 | 1 | |a Satake, Eiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Saulnier, Pierre Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Md Dom, Zaipul I |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neil, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Ihara, Katsuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Krolewski, Bozena |e verfasserin |4 aut | |
| 700 | 1 | |a Galecki, Andrzej T |e verfasserin |4 aut | |
| 700 | 1 | |a Niewczas, Monika A |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Doria, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Duffin, Kevin L |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Robert G |e verfasserin |4 aut | |
| 700 | 1 | |a Krolewski, Andrzej S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international |d 1972 |g 102(2022), 2 vom: 01. Aug., Seite 370-381 |w (DE-627)NLM000007188 |x 1523-1755 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2022 |g number:2 |g day:01 |g month:08 |g pages:370-381 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.kint.2022.04.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2022 |e 2 |b 01 |c 08 |h 370-381 | ||